

CURRICULUM VITAE

Curtis L. Hagedorn, MD

Edited September 2021

MEDICAL LICENSE. Colorado - 43556
NPI: 1508863382

COLORADO RETINA ASSOCIATES: Since 09/2008

BOARD CERTIFICATION. Diplomate, American Board of Ophthalmology since 2004

EDUCATION AND TRAINING

COLLEGE Colorado College
Colorado Springs, CO
B.A. Biology, cum Laude (GPA3.75/4.00)
Blue Key Honor Society, Order of Omega Honor Fraternity,
Alpha Lamda Delta Honor Society, Packard Academic
Scholarship

MEDICAL SCHOOL: Rush Medical College
Chicago, IL September 1995 — June 1999 M.D.
1999, Alpha Omega Alpha — 1998
Dean Medical Student Summer Research Fellowship, 1995

INTERNSHIP. Resurrection Medical Center
Chicago, IL July 1999 - June 2000

RESIDENCY: Yale University
New Haven, CT
Ophthalmology, July 2000 — June 2003
Marvin Sears Award for Clinical Excellence: June 2002
➤ Awarded to one outstanding resident each year.

FELLOWSHIPS. Yale University
New Haven, CT
Vitreoretinal Surgery/Clinical Instructor July
2003 - June 2005

PROFESSIONAL

SOCIETIES: American Academy of Ophthalmology, Board Certified since 2014
International Society of Stem Cell Research
American Eye Study Club 2015 - present
American Society of Retina Specialists
Association for Research in Vision and Ophthalmology
American Medical Association
Colorado Society of Eye Physicians and Surgeons

CURRENT POSITIONS: Partner, Colorado Retina Associates, PC
Denver, CO (September 2008 — present)
President (2013-2014)

PAST POSITIONS. Retina Consultants of Colorado, PC
Denver, CO (September 2005 — August 2008)

LEADERSHIP &
PROFESSIONAL

ACTIVITIES.

Colorado Medical Society

- Board of Directors 2014 — present

Denver Medical Society

- Chairman of the Board 2013 — 2014
- president 2012-2103
- Board of Directors 2009 - 2014

Denver Medical Society Foundation Board
Member 2015 - present
Chairman — Department of Ophthalmology
St. Joseph's Hospital
Denver, CO 2007 - 2012
Delegate - Colorado Medical Society House of Delegates, 2010 to present.
Colorado Medical Society Annual Meeting Reference Committee, 2012, 2013
Alternate delegate - Colorado Medical Society House of Delegates, 2006 - 2010.
Member: Operating Room Council. St. Joseph's Hospital
Denver, CO 2007 - 2009
Ophthalmology representative - Graduate Medical Education Committee, 2002 - 2003
Creator: Yale Eye Center Graduation Creative Video Production 2001 and 2002
Volunteer: Lion's Club Eye Screening: 4/2001

Vice President: Rush AMA Student Section 1996 - 1997
Treasurer: Lecture note CO-OP committee 1995 - 1997
Volunteer: Rush Community Service Initiatives Program
Clinics: St. Basil's Free People's Clinic, Franciscan Homeless Shelter, Pilsen Community Clinic. 1995 - 1997
Volunteer participant in pilot preceptorship program 1995 — 1997.
• Spent 1 -2 afternoons per month with Geriatric Homecare M.D. and acted as assistant/primary caregiver during nursing home and private home visits.
Physiology Tutor for Medical Students 1996 - 1997
Chairperson for Medical Student Big Sib/Little Sib Committee 6/96 - 9/96
Creator: End of Preclinical Years Creative Video Production 1997 and End of Medical School Creative Video Production 1999
Rush Medical College intramural flag football player and official 1995 and 1996 Volunteer patient transporter at University Hospital in Denver, Colorado 1994 - 1995
Lab Technician at Rocky Mountain Orthotics Lab in Denver, Colorado 1994 -1995
Morgue Deaner at Penrose Community Hospital in Colorado Springs, CO 1992 – 1993

RESEARCH/PUBLICATIONS

1. Fliney GD, Zukin LM, Hagedorn CL: Neovascular Age-Related Macular Degeneration Disease Quiescence with Visual Acuity Stability in a Subgroup of Patients Following PRN Treatment. *Journal of Ocular Pharmacology and Therapeutics*; 2017 Oct; 33(8).
2. Zablocki C, Hagedorn CL: Chorioretinal atrophy after electrical injury. *Digital Journal of Ophthalmology*; 2011 Sep; 17(3).
3. Hagedorn CL, Adelman RA: Age-related Macular Degeneration in Ocular Angiogenesis, Ed: Tombran-Tink J, Barnstable CJ. 2006.
4. Arya AV, Emerson, JW, Engelbert M, Hagedorn CL, Adelman RA: Surgical Management of Pseudophakic Retinal Detachments: A Meta-analysis. *Ophthalmology*; 2006 Oct; 113(10). 172-1-33.
5. Hagedorn CL, Lucas TL, Adelman RA: Significance of Fluorescein Angiogram Retinal Filling Time in Age-Related Macular Degeneration. Presented at ARVO Annual Meeting, 2005. Abstract published in *Investigative Ophthalmology and Visual Science*; May 2005.
6. Arya AV, Njike VY, Hagedorn CL, Engelbert M, Adelman R: Anatomical and Functional Outcome With Various Surgical Techniques in the Management of Pseudophakic Retinal Detachments. Presented at ARVO Annual Meeting, 2005. Abstract published in *Investigative Ophthalmology and Visual Science*; May 2005.
7. Vora SR, Hagedorn CL, Khan N, Aslan M, Concato JP, Adelman RA: Is Repeat Macular Laser Photocoagulation Effective in the Management of Diabetic Macular Edema?

- Presented at ARVO Annual Meeting; 2005. Abstract published in Investigative Ophthalmology and Visual Science; May 2005.
8. Macular Degeneration and Cataract Surgery. Randomized study at Yale University. Coinvestigator 2003-2005.
 9. Hagedorn CL, Adelman RA, Tauber S: Bilateral Intraocular Foreign Bodies Simulating Crystalline Lens. American Journal of Ophthalmology; Volume 138, Issue 1, July 2004, Pages 146-147.
 10. Adelman RA, Hagedorn CL: Sympathetic Ophthalmia Following Pneumatic Retinopexy. Presented at ARVO Annual Meeting, 2004. Abstract published in Investigative Ophthalmology and Visual Science; May 2004.
 11. Diaz VA, Hagedorn CL, Menn K, Stout R, Shelley K, Gesquire M, Tomai D, Silverman D, Adelman RA: Laser Doppler Flowmetry Study of Systemic Vasoconstriction after Topical 2.5% Phenylephrine Eye Drops. Presented at ARVO Annual Meeting, 2004. Abstract published in Investigative Ophthalmology and Visual Science; May 2004.
 12. Hagedorn CL, DeBroff BM, Candal EM, Dragan L, Reistad C, Jirawuthiworavong G: 1 Year Study Results Evaluating Pupil Size and Complications in Phacoemulsification Cataract Surgery During Residency Training: Presented at ARVO Annual Meeting, 2003. Abstract published in Investigative Ophthalmology and Visual Science; May 2003.
 13. Hagedorn CL, DeBroff BM, Candal EM, Dragan L: Pupillometry as a Predictor of Complications in Cataract Surgery: Presented at ARVO Annual Meeting, 2002. Abstract published in Investigative Ophthalmology and Visual Science; May 2002.
 14. Smith MC, Hoepfner T, Hagedorn C: Spontaneous Seizures in Kindled GEPR Rats. *Epilepsia* 1997; vol 38, Supplement 3: 176-177.
 15. Hagedorn CL: A Sort of Homecoming (Creative writing piece). *Journal of General Internal Medicine*; November 1998; vol 13, No. 11: 767.
 16. "The Effects of Amygdala Kindling on Fear Conditioning in Valproate Treated Rats" Advisors: Michael Smith, M.D. and Thomas Hoepfner, PhD. 1995-1999.
 17. Molecular Biology: Development of Instant Caffeine Indicator Using ELISA Technique Advisor: Ralph Bertrand, PhD. 1994.
 18. **FOVISTA** - A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of FOVISTA™ (ANTI-PEGYLATED APTAMER) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration. CO-investigator. 2015 to 2017.
 19. **FOVISTA** - A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the safety and Efficacy of Intravitreal Administration of FOVISTA™ (ANTI-PEGYLATED APTAMER) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration. Co-investigator. 2014 to 2017.

20. **Oculos-** Phase 2 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Co-investigator. 2012 to 2015.
21. **Forsight-** A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis. Coinvestigator. 2014 to 2015.
22. **ORA-** A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 months, as Monotherapy or Adjunctive to Ranibizumab, In Subjects with Diabetic Macular Edema. Co-investigator. 2014 to 2015.
23. **TOGA-** A Randomized, Double-Masked, Placeho Controlled Study Evaluating ORACEA@ in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration. Co-investigator. 2014 to present.
24. **ORBIT (Ocriplasmin Research to Better Inform Treatment)** Co-investigator. 2014 to 2016.
25. **STOP-** Study of the Safety, Tolerability, and Bioactivity of Tocilizumab on Patients with NonInfectious Uveitis. Co-investigator. 2012 to 2017.
26. **EYEGUARD A-** A Randomized, Double-Masked, Placebo Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-Infectious Intermediate, Posterior, Or Pan-Uveitis; Co-investigator. 2012 to 2015.
27. **EYEGUARD-** A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with non-infectious intermediate, posterior, or pan-uveitis currently controlled with systemic treatment. Co-investigator. 2012 to 2015.
28. **OPTINA-** A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema. Co-investigator. 2012 to 2015.
29. **SHORE FVF4967g Genentech: A MULTICENTER RANDOM IZED STUDY EVALUATING DOSING REGIMENS FOR TREATMENT WITH INTRAVITREAL RANIBIZUMAB INJECTIONS IN SUBJECTS WITH MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION** Co-investigator. 2011 to 2012.
30. **BAM-** A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related macular Degeneration. Co-investigator. 2013 to 2016.
31. **REVIEW-** An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Afibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration. Co-investigator. 2013 to 2015.
32. **SEATTLE-** A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU--4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry Age-Related Macular Degeneration. Co-investigator. 2013 to 2016.

33. **VISTA**: VCFT-OO-1009: A Double-Masked, Randomized, Active-controlled. Phase 3
34. Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Sponsor-Regeneron. **Principal Investigator**. 2011 to 2015.
35. **SAKURA**. Protocol No. 32-007: A Phase 3, Multinational, Multicenter, Randomized,
 36. Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of
 37. DE-1 09 (three doses) for the Treatment of active, Non-infectious Uveitis of the Posterior Segment of the eye. Sponsor-Santen Incorporated. Co-investigator. 2011 to 2017.
38. **GSK MD7110852**: A Phase 2b Dose-Finding Study of Pazopanib Eye Drops versus Ranibizumab Injections for the Treatment of Neovascular Age-Related Macular Degeneration Sponsor-CSK. Co-investigator. 2011
39. **CAIN**: 457A2208: An open-label proof-of-concept study with a double-masked, dose ranging component to assess the effects of AN457 in patients with noninfectious uveitis. Sponsor-Novartis. Co-investigator. 2011 to 2013.
40. **DNA Repository Sub Study in Association with Ranibizumab Study FBF4579g: (Genentech)**: A Phase 3, Double-Masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients with Subfoveal Neovascular Age-related Macular Degeneration. Co-investigator. 2009 to 2011.
41. **RISE**- A Phase 3, Double-masked, Multicentered, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. **Principal Investigator**. 2007 to 2012.
42. **VIEW**- A Randomized, Double Masked, Active Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration, VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD. **Principal investigator**. 2007 to 2011.
43. Phase 3 Trial to Establish the Safety and Efficacy of Intravitreal Injections of EYEOOI (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 weeks, in Patients with Exudative Age-Related Macular Degeneration (AMD). Co-investigator. 2004-2005.
44. Phase 3 Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 in Patients with Minimally Classic or Occult Choroidal Neovascularization (CNV) due to Age-Related Macular Degeneration (AMD). Co-investigator. 2004-2005.
45. An Evaluation of Efficacy and Safety of Posterior Juxtapapillary Injections of Anecortave Acetate 15 mg (0.5 mL of 30 mg/mL Anecortave acetate sterile suspension) versus VISUDYNE in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD) Eligible for Initial Treatment with Photodynamic Therapy (PDT) Using Visudyne. Co-investigator. 2004-2005.
46. Phase 3 Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 Compared with Verteporfin Photodynamic Therapy in Subjects with Predominantly Classic Neovascular Age-Related Macular Degeneration. Co- investigator. 2004-2005.
47. Protein Kinase C β Inhibitor - Diabetic Retinopathy Study 2 (PKC-DRS2). A Phase 3 Clinical Trial. Co-investigator. 2003-2005.
48. **EMERGE (Iconic)**- Protocol: IT-002, Sub-investigator, Title: A Phase II, Randomized, Double-Masked, Multicenter, Active-controlled study evaluating the safety of Repeated

Intravitreal injections of HL-Con1 administered as monotherapy or in combination with Ranibizumab compared to ranibizumab monotherapy. 2015-2016

49. **XCOVERY (Tyrogenex):** Sub-Investigator, Protocol: X82-OPH-201, Title: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-inferiority study of the X-82 plus prn Eylea monotherapy in Neovascular AMD 2015-2017.
50. **Spectri (LAMPA):** Sub-Investigator, Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic atrophy secondary to Age-Related Macular Degeneration, 2015-2018.
51. **Neurotech:** Sub-Investigator, Protocol: NT-503-3-AMD-001, Title: A Multi-Center, two-stage, open-label Phase I and Randomized, Active Controlled, Masked Phase II study to evaluate the safety and efficacy of intravitreal implantation of NT-503-3 Encapsulated Cell Technology compared with Eylea for the treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) 2015-2016.
52. **Ladder (Genentech):** Sub-Investigator, Protocol: GX28228, Title: Active treatment-controlled study of the efficacy and safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in patients with Subfoveal Neovascular Age-related Macular Degeneration 2015-present.
53. **Vidi (Astellas):** Sub-investigator- Protocol: 8232-CL-OOI, Title: A Phase II, Double-Masked, Randomized, Active-controlled study to evaluate the efficacy and safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema 2015-2016
54. **HAWK (ALCON):** Sub-Investigator, Protocol: RTH258-C001, Title: A two-year, Randomized, Double-Masked, Multi-Center, Three Arm Study comparing the Efficacy and Safety of RTH258 versus Aflibercept in subjects with Neovascular age-related Macular Degeneration 2015-2018.
55. **CAPELLA (Regeneron): Principal Investigator,** Protocol: R2176-AMD-1417, Title: A Phase II, Double-Masked, Randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with Neovascular Age-Related Macular Degeneration 2015-2017.
56. **CEDAR (ALLERGAN):** Sub-Investigator, Protocol: AGN-150998, Title: A Multicenter, Double-masked, Randomized 100-week Parallel-group, Active-controlled study to evaluate the safety and efficacy of Abicipar in treatment-naïve patients with Neovascular AMD. 2015- present
57. **VAPOR (SANTEN),** Sub-Investigator, Protocol: 35-002, Title: A Multi-Center, Randomized, Open label, Phase IIa Study Assessing the Efficacy, safety and duration of effect on intravitreal injections of DE-120 (a VEGF and PDGF Receptor Inhibitor) as monotherapy and with a single Eylea injection in subjects with Treatment Naïve Exudative Age-Related Macular Degeneration. 2015-2017.
58. **ALDERYA:** Sub-Investigator, Protocol: NS2-02, Title: A Phase 2, Randomized Investigator Masked, Comparator controlled trial to evaluate the safety and efficacy of NS2 Eye Drops in Patients with Anterior Uveitis. 2015-2016
59. **AVENUE (ROCHE):** Sub-Investigator, Protocol: BP29647, Title: A Multicenter Multiple dose and regiment, randomized, active comparator controlled, double-masked, parallel group, 36-Week study to investigate the safety, tolerability and efficacy of R06867461 Administered Intravitreally in Patients with Choroidal Neovascularization secondary to Age-Related Macular Degeneration. 2015-2018

60. **PROXIMA (Genentech):** Sub-Investigator, Protocol: GX29633, Title: A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration 2015-2018
61. **LHA510 (ALCON/NOVARTIS):** Sub-Investigator, Protocol: LHA510-2201, Title: A Randomized, Double-Masked, Vehicle-Controlled, Proof-of-Concept study for Topically delivered LHA510 as a maintenance therapy in patients with Wet Age-Related Macular Degeneration. 2015-2017
62. **AURA (Aura Biosciences):** Sub-Investigator, Protocol: AU-011-201, Title: A prospective, Randomized, Multi-center, masked clinical trial designed to evaluate two doses of Light-Activated AU-011 for the treatment of subjects with small to medium (1.5-4.0 mm thickness) Primary uveal Melanoma. 2016-2018
63. **PANORAMA (Regeneron): Principal Investigator,** Protocol: VGFTe-OD-1411, Title: A Phase 3, Double-Masked, Randomized study of the efficacy and safety of Intravitreal Aflibercept injection in patients with moderately severe to severe Nonproliferative Diabetic Retinopathy, 2016-present
64. **Exposure (Genentech),** Sub-Investigator, Protocol: GX29455, Title: A Phase II Multicenter, Randomized, Single-Masked, Sham injection- study of Lampalizumab Intravitreal injections administered to patients with Geographic Atrophy. 2016-2017
65. **EYEGATE:** Sub-Investigator, Protocol: EGP-437-006, Title: A Prospective, Multi-center, Randomized, Double-Masked, Positive Controlled, Phase 3 clinical trial designed to evaluate the safety and efficacy of Iontophoretic Dexamethasone phosphate Ophthalmic solution compared to Prednisolone Acetate Ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis. 2016-present
66. **ABICIPAR DME:** Sub-Investigator, Protocol: 1771-201-008, Title: A multicenter, open-label, single-arm study to evaluate Abicipar for safety and treatment effect in patients with neovascular age-related macular degeneration (AMD) 2017-present
67. **AERPIO/TIME2B:** Sub-Investigator, Title: A Phase 2, Double-Masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with Moderate to severe Non-proliferative diabetic Retinopathy 2017-present
68. **OLEi:** Sub-Investigator, Title: A Phase II, multicenter, randomized, single-masked, sham injection study of Lampalizumab intravitreal injections administered to patients with Geographic atrophy who have completed prior Lampalizumab studies, 2016-2017
69. **STAIRWAY:** Sub-Investigator, Title: This is a Phase II, multicenter, randomized, active comparator-controlled, subject and outcome assessor masked, parallel group, 52-week study to investigate the efficacy, safety and pharmacokinetics of RO6867461 administered at 12- and 16- week intervals in treatment-naïve patients with nAMD 2016-2017
70. **TLC399A2002:** Sub-Investigator, Title: A Phase Trial of TLC399 (ProDex) in subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A Double-masked, randomized trial to evaluate the efficacy and tolerability. 2016-present
71. **HAWK Extension:** Sub-Investigator, Protocol: RTH258-C001, Title: A Two-year Randomized, Double-Masked, Multicenter, Three-arm study comparing the efficacy and safety of RTH258 versus Aflibercept in subjects with Neovascular Age-Related Macular Degeneration who participated in the Hawk I Study. 2017-present
72. **BOULEVARD:** Sub-Investigator, Protocol: BP30099, Title: A multicenter, multiple dose randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in patients with CI-DME. 2016-2017

73. **ICONIC:** Sub-Investigator, Protocol: IT-003, Title: A Phase 1, open-label, multicenter study evaluating the safety and tolerability, biologic activity, pharmacodynamics and pharmacokinetics of single and repeated escalating intravitreal doses of ICON-1 in patients with Uveal Melanoma who are planned to undergo Enucleation or Brachytherapy. 2016-2017
74. **SAPPHIRE:** Sub-Investigator, Protocol: CLS1003-301, Title: A Randomized, masked, controlled trial to study the safety and efficacy of Suprachoroidal CLS-TA in conjunction with intravitreal Aflibercept in subjects with Retinal Vein Occlusion. 2016-present
75. **GILEAD:** Sub-Investigator, Title: A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the efficacy and Safety of Filgotinib in subjects with Active Noninfectious Uveitis. 2018-present
76. **PEACHTREE:** Sub-Investigator, Title: A Phase 3, Randomized, masked, controlled clinical trial to study the safety and efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the treatment of subjects with Macular Edema associated with Non-infectious Uveitis. 2016-2017.
77. **OPT-302: Principal Investigator,** Title: A Dose-ranging study of intravitreal OPT-302 in combination with Ranibizumab in participants with wet AMD. 2018-present
78. **OPH2003B:** Sub-Investigator, Title: A Phase 2/3 Randomized, Double-Masked, controlled trial to assess the safety and efficacy of Intravitreal Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. 2018-present
79. **OPH2007:** Sub-Investigator, Title: A Phase 2A open label to assess the safety of Zimura™ (Anti-C5 Aptamer) administered in combination with Lucentis 0.5mg in nAMD. 2018-present

LECTURES/TEACHING

- Mile High Masters of Retina. Denver, CO. Clinical Lecturer. 2011 — present.
- Preceptor: Foundations of Doctoring. University of Colorado Medical School, Denver, CO. 2009 to present.
- High Tech High School Careers in Medicine lecture Series. Denver, CO. Guest lecturer to High School Sophomores and Juniors. February 2014.
- Invited Lecturer at Diabetes Expo in Denver, CO. February 2006.
- Visiting professorship-Hospital Luis Sanchez-Bulnes, Mexico City, Mexico. July 2005.
- Speaker at Yale Spring Symposium: Emerging Trends in Treatment of Diabetic Macular Edema. June 4, 2004.
- Speaker at Yale Ocular Trauma Symposium. April 4, 2004.
- Retina OKAP review for residents. 1/04-4/04
- Hagedorn CL, Adelman RA, Tauber S. Management of bilateral ocular penetrating injury and diagnosis of intraocular foreign bodies. Presented at the Third European VitreoRetinal Society Congress. Sixth International Society of Ocular Trauma; Sopron, Hungary. September 2003.

- Monthly retina lectures to residents. 7/03-7/05
- Lecture to physician assistant students: Pediatric Eye Disease. 4/2003
- Workshop for medical students: Eye Emergencies. 3/2003
- 13Week OKAP Review for Yale Residents. 1/03-4/03
- Lecture to 2^d year medical students: Ocular Manifestations of Systemic Disease. 3/2002.
- Lecture to ER physicians: Pediatric Eye Emergencies. 10/2001
- Elected CPC Discussant, Alumni Day: 6/99
 - Graduating medical school class elects one outstanding classmate to give annual lecture.